A fter an acute myocardial infarction, women continue to experience higher mortality than men, despite improvements in reperfusion therapy. 1, 2 This worse outcome is attributed, at least in part, to older age at presentation, though a recent meta-analysis of observational studies has reported that women have a higher risk of in-hospital mortality even after adjustment for baseline differences. 3 Over the last 15 years, there has been a progressive improvement in reperfusion therapy for ST-elevation myocardial infarction (STEMI), with a shift from fibrinolytic therapy to primary percutaneous coronary intervention (pPCI) and an overall increase in reperfusion rates due to the organization of STEMI networks. These improvements in STEMI treatment had the potential to reduce the gap in STEMI outcomes among women, given that in the lytic era they consistently received less treatment and were more exposed to adverse bleeding events following fibrinolysis. On the other hand, use of pPCI virtually eliminates the risk of intracranial bleeding and has been shown to be an independent predictor of survival in women. 4 In the present study, we describe the evolution of reperfusion therapy for STEMI from 2001 to 2014 in Italy, taking into account sex differences in in-hospital treatment and outcome across age groups among patients admitted to cardiac care units (CCUs) with a diagnosis of STEMI and enrolled in nationwide registries. 8 and EYESHOT (EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units) in 2013 and 2014. 9 All surveys were nationwide and included patients with ACS consecutively admitted alive to the participating CCUs during a prespecified period (a few weeks for the BLITZ and EYESHOT registries and 1 year for IN-ACS Outcome and MANTRA) ( Table 1 ). The methods used for each registry have been described previously. [5] [6] [7] [8] [9] Briefly, their primary objectives were to evaluate the clinical characteristics, management, and outcomes of consecutive patients with ACS admitted to Italian CCUs, using a catchment method broad enough to provide data representative of the entire country. Participation in the various registries had been offered to all institutions in BLITZ and EYESHOT, to CCUs able to enroll at least 40 ACS patients over 10 weeks in BLITZ 4, and to a representative sample of CCUs (balanced by geographical region and hospital complexity) in IN-ACS Outcome and MANTRA. The percentages of Centers with on-site cath-lab are reported in Table 1 . Physicians were instructed that participation in the registries should not affect clinical care or management. Informed consent was obtained from all patients who were aware of the nature and aims of the registries. Local Institutional Review Boards were informed of the study according to the Italian rules and approved the protocol.
Methods

Data Collection
Data on baseline characteristics, including demographics, risk factors, and medical history, were collected as previously described. [5] [6] [7] [8] [9] Information on the use of cardiac procedures, including coronary angiography, type of revascularization therapy (if any), use of medications during hospitalization and at hospital discharge, and in-hospital major clinical events, were recorded. In the BLITZ 4 registry, door to balloon time was available only for patients presenting to hospitals with on-site pPCI facilities. For the present analysis, only patients with a final diagnosis of STEMI on admission were considered. The definitions of inclusion criteria and outcome events were consistent throughout the surveys. STEMI was defined as STsegment elevation >1 mm (0.1 mV) in 2 or more contiguous precordial leads or in 2 or more adjacent limb leads, or new or presumed new left bundle branch block associated with symptoms suggestive of ACS. Re-infarction during initial hospitalization was diagnosed in the presence of new ischemic symptoms and a re-elevation of biochemical myocardial necrosis markers with or without concurrent ECG changes. Major bleeding was classified according to the Thrombolysis In Myocardial Infarction (TIMI) criteria. 10 Stroke was identified as an acute neurologic deficit lasting >24 hours and affecting the ability to perform daily activities with or without confirmation by imaging techniques. Cardiogenic shock was defined as systolic blood pressure (BP) of ≤90 mm Hg lasting >60 minutes, nonresponsive to fluid challenge or requiring the administration of inotropic drugs in order to obtain a systolic BP of >90 mm Hg, with clinical signs of peripheral hypoperfusion such as sensorial obnubilation, low urine output (<30 mL/h), cold sweat, or cyanosis.
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All data were collected at hospital discharge using a case report form at the participating centers and entered in a centralized database located at the ANMCO Research Center in Florence, Italy. By using a validation plan integrated in the data entry software, data were checked with data queries for missing or contradictory entries and values out of the normal range. The data were also centrally audited at the coordinating center. If the queries were not answered by the investigators, the data were considered as missing. analysis (logistic model) was performed to estimate the risk of in-hospital mortality over time adjusted for study cohort, reperfusion therapy, type of hospital, geographic area, and for risk factors and baseline characteristics significantly associated with in-hospital mortality at a previous univariate analysis. These variables were continuous (age, baseline systolic blood pressure, and heart rate), dichotomous (female sex, smoking, diabetes mellitus, hypertension on treatment, prior angina, prior myocardial infarction, prior heart failure, peripheral artery disease, prior stroke/transient ischemic attack, prior renal dysfunction, Killip class IV at entry, atrial fibrillation, anterior myocardial infarction, hospital with cath-lab) and categorical. In the latter case, dummy variables were introduced to define a reference group: reperfusion therapy (no reperfusion [reference group]; pPCI; lysis), geographic area (north [reference group], center, south), and the study cohort (2001 as reference group). The interaction term between sex and age was also inserted in the model. We also performed the same multivariable analysis for men and women separately. Furthermore, a logistic model on in-hospital mortality was performed with only age, sex, and their interaction term, considering age in the prespecified classes instead of in continuous. Finally, a logistic model on in-hospital mortality was conducted adjusting for sex, study, and their interaction term.
Statistical Analysis
All tests were 2-sided; a P<0.05 was considered statistically significant. All analyses were conducted with SAS system software version 9.2 (SAS Institute Inc, Cary, NC).
Results
Patient Characteristics
Of 28 274 patients with ACS enrolled in the 5 registries, 13 235 (46.8%) were classified as having STEMI (72.1% men and 27.9% women). The overall rates of women with STEMI did not change significantly over time (from 30.1% in 2001 to 28.1% in 2014; P for trend=0.06) ( Table 1 ). The prevalence of women increased significantly with age, being 13.0% in the age class <55 years, 17.5% in the age class 55 to 64 years, 28.0% in the age class 65 to 74 years, and 48.3% in the age class ≥75 years (P for trend <0.0001), resulting in a higher mean age of women compared with men (72AE13 versus 63AE12 years, P<0.0001).
Sex and age differences in clinical characteristics of patients with STEMI enrolled during the study period are listed in Table 2 . When compared to men in the majority of corresponding age categories, women were less likely to be active smokers, had more hypertension and lower rates of prior myocardial infarction or revascularization procedures. Killip class IV on admission increased significantly with age in both sexes and was slightly more frequent among women in all age classes, even though a significant difference was observed among patients aged <55 years. The use of antithrombotic therapies during hospital admission was significantly lower with the increase in age classes for both sexes. When compared to men, women aged ≥65 years received significantly less unfractionated heparin, glycoprotein IIb/IIIa inhibitors, and dual antiplatelet therapy during hospitalization (Table 2 ).
Changes in Reperfusion Therapy
As shown in Figure 1 , the use of fibrinolytic therapy decreased from 2001 to 2014 in both sexes and at all ages (all P for trend <0.0001), and this trend was mirrored by a dramatic increase in pPCI, also affecting both sexes at all ages (all P<0.0001). The overall rates of no reperfusion therapy decreased significantly (P for trend <0.0001), and the changes were particularly marked among women aged ≥75 years (from 64.1% in 2001 to 27.1% in 2014). The no reperfusion rates remained significantly higher in older women until 2010, but tended to disappear in 2014. Among patients receiving pPCI, no significant differences were observed between men and women with regard to door to balloon times (2.2AE4.7 versus 1.7AE1. 
In-Hospital Outcomes
As shown in Table 3 , crude in-hospital mortality rates increased significantly with age in both sexes, being significantly higher in women at all ages (except in patients <55 years of age, who presented an extremely low in-hospital fatality rate). The rates of reinfarction increased significantly with age in men, but not in women, whereas the rates of stroke and cardiogenic shock increased significantly with age in both sexes. The rates of TIMI major bleeding were significantly higher in women at all ages compared to men and increased significantly with age in men, but not in women.
Time trends for mortality according to age are shown in Figure 2 , with an overall decline in mortality over time affecting both sexes (P for trend <0.01) and patients aged ≥75 years (P for trend <0.0001). Mortality and reinfarction rates declined significantly over time in both sexes, whereas stroke rates remained fairly stable, being slightly higher among women at all time points (Table 4) . Overall cardiogenic shock rates were significantly higher in women (8.6% versus 4.8%, P<0.0001), even though statistically significant only in patients aged 65 to 74 years, and declined significantly over time in women and not in men. Furthermore, cardiogenic shock fatality rates were higher in women at all time points, except for year 2001 (Figure 3 ), but were statistically significant only in year 2009. Major bleeding rates were significantly higher among women, and there was no significant trend over time in both sexes. On multivariable analysis, several variables were found to be significantly related to in-hospital mortality (Figure 4 ), but without a statistically significant interaction between sex and age (P for interaction=0.61). The c-statistic for this model was 0.881. Many variables remained predictors of mortality even when the model was applied separately to men and women (c-statistic=0.892 and =0.837, respectively) ( Figure 5) . In a further model adjusted only for sex and age, considering the 4 prespecified age classes, the interaction between sex and age remained not significant (P for interaction=0.21). Comparing women to men, the adjusted odds ratios for in-hospital mortality were 0.74 (95% CI 0.17-3.22) for age <55 years, 2.55 (95% CI 1.43-4.55) for age 55 to 64 years, 1.80 (95% CI 1.22-2.67) for age 65 to 74 years, and 1.48 (95% CI 1.21-1.81) for age ≥75 years. Finally, in the model where only sex and year of the study were considered, no significant interaction between these 2 variables was observed (P for Figure 1 . In-hospital rates of primary PCI (A, B), thrombolysis (C, D), and no reperfusion (E, F) over time, among men and women, according to age classes. PCI indicates percutaneous coronary intervention.
interaction=0.95), suggesting that the risk of death for women was higher than that for men, and this excess risk did not change over the years.
Discussion
The present analysis covers a period of time where reperfusion therapy for STEMI changed dramatically with the nationwide organization of STEMI networks. 12 In the present study, we observed a striking increase in pPCI, a concomitant reduction in fibrinolysis and, more importantly, a significant reduction in the rates of no reperfusion affecting both women and men and all age classes. These positive changes in reperfusion therapy resulted in significantly lower mortality rates for both sexes over time, but the worse outcome of women, as compared to men, remained unchanged among all age classes, except for women aged <55 years. A second point of interest in the present study was the comparison of men and women across age classes to verify whether the unfavorable treatment and mortality gaps reported for women were, at least in part, dependent on women's older age. Our data show that, at least until 2010, the rates of no reperfusion remained significantly higher among women aged ≥75 years compared to men, and this gap disappeared only in 2014. On multivariable analysis, both age and female sex were found to be significantly associated with in-hospital mortality after adjustment for other risk factors, but without any mutual interaction. From the present analysis, 3 causes emerge as possible culprit in persistently higher mortality rates among women with STEMI compared to men: (1) significantly less reperfusion therapy; (2) a higher major bleeding rate; and (3) more prevalent and more fatal cardiogenic shock. Lower reperfusion rates in women, as compared to men, have been reported since the early thrombolytic era, 2 and this gap continues to persist. [13] [14] [15] In the present analysis, women in any class of age were less likely to receive either pPCI or thrombolysis than men, although the overall rate of reperfusion increased over time. Several reasons can be postulated to explain these findings. 2 For instance, women with STEMI are more likely to have atypical symptoms possibly leading to delayed presentation and under-recognition of STEMI at first medical contact, thus precluding early reperfusion strategies. 2, [16] [17] [18] Despite an overall increase in emergency coronary angiography, lower reperfusion rates in women can also be explained by a higher frequency of alternative etiologies (eg, spontaneous coronary dissection, coronary vasospasm), and different angiographic findings. 19 Indeed, the OCTAVIA (Optical Coherence Tomography Assessment of Gender Diversity in Primary Angioplasty) study, the first prospective controlled study designed to assess in vivo sex differences in the mechanisms of STEMI, demonstrated that men and women, when matched for age, shared similar prevalence of ruptured and eroded plaques. 20 These findings suggest that disparities in environment, behavior, risk factors, and management, rather than different biological mechanisms and response to treatment, might be more relevant in affecting clinical outcome. We observed higher rates of major bleeding in women than in men, particularly among those aged >55 years, even though no significant trend was observed over age. A higher risk of bleeding in women has been known since the early fibrinolytic era, 21 when the ISIS-3 collaboration observed a 70% excess in major bleeding among women, as compared to men, after adjustment for age and other risk factors. This increased risk persisted after the reperfusion shift to pPCI 22 and is independently associated with a 3-fold increase in mortality. 23 The higher risk of bleeding among women might be partly related to the lack of weight or body mass dose adjustment of most antithrombotic drugs, and also to a lower use of radial access among women who, compared with men, have smaller radial arteries that may be more prone to spasm, which is a major cause of radial procedure failure. 24 The rates of cardiogenic shock due to acute coronary syndromes have decreased in our country during the observation period, as well as overall mortality due to cardiogenic shock. 11 Yet, as shown by the present data, case fatality rates have been declining more significantly among men than among women. Women in our study had higher rates of cardiogenic shock as compared to men at any age, both upon admission and during subsequent hospital stay, even though a significant difference was observed among the 65 to 74 years group, and at least part of the excess mortality among women should probably be attributed to a higher incidence of cardiogenic shock. Both female sex and age have been shown to be independent predictors for the occurrence 20, 25 and mortality 26 of cardiogenic shock in STEMI, even after the widespread use of acute reperfusion therapy. Longer delay to reperfusion among women may be the major reason for both the higher incidence and case fatality of cardiogenic shock. Focusing future research and quality initiatives on these 3 potential causes of worse outcome in women with STEMI has the potential to reduce the persisting mortality gap for women in STEMI. System efforts to reduce the time from symptom onset to reperfusion are strongly endorsed by practice guidelines, 27, 28 though the effectiveness from public campaigns has not yet been clearly established. According to our data, the implementation of STEMI networks in Italy has improved the rates of reperfusion in both women and men. Among the strategies to reduce bleeding, probably the most effective was the gradual shift from fibrinolysis to pPCI, but also the later shift from the femoral to the radial vascular approach to PCI, which has been shown to improve outcomes and reduce bleeding particularly among women. 29 Finally, according to our data and other all-comers observational studies, mortality in cardiogenic shock complicating acute coronary syndromes remains higher in women than in men. Therefore, further studies are warranted to better define specific treatment strategies in cardiogenic shock. 30 
Conclusions
Despite a dramatic shift from thrombolysis to pPCI and an overall reduction in no reperfusion therapy over time, affecting both sexes and all age classes, women continue to show a significantly higher adjusted risk of in-hospital mortality, as compared to men. Cardiac societies from both sides of the Atlantic have released specific documents on sex differences in presentation, treatment, and outcomes of Figure 5 . Multivariable logistic regression analysis for in-hospital factors related to mortality over time in men (A) and women (B). HR indicates heart rate; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TIA, transient ischemic attack. cardiovascular disease, 2,31 though prospective studies aimed at investigating the reasons for the persisting worse outcomes of STEMI in women are still lacking. 32 
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